This company as no revenue still high expenses ongoing losseThey cancelled ivig last year at phase 3 now they cancelled ryplasim also at phase 3 with excellent results and fda as no issues with the product they ONLY WANTED 4 CHECKPOINTS DURING production then get approval for market
WHY DID THEY CANCEL A PRODUCT READY FOR MARKET WHAT ARE THEY NOT TELLING US
WHY PUT THEIR FOCUS ON PRODUCT YEARS BEFORE IT MAY GET APPROVED
next yearly update will they give retail investors a chance to ask them questions
will they clarify whether or not consonance did sell their shares and take a huge loss
mister Thompson can't be happy with his team who orchestrated takeover since sp just kept decreasing since they wiped out shareholders